Literature DB >> 2459123

Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

P J Declerck1, M De Mol, M C Alessi, S Baudner, E P Pâques, K T Preissner, G Müller-Berghaus, D Collen.   

Abstract

A binding protein for plasminogen activator inhibitor 1 (PAI-1-BP) was isolated from human plasma by a four-step procedure. 1) The 7 S globulin fraction of plasma was isolated by gel filtration on Sephacryl S-300. 2) Human endothelial cell-type plasminogen activator inhibitor (PAI-1), pretreated with 12 M urea, was added to this fraction (22 micrograms of PAI-1/ml of plasma), and a PAI-1 antigen peak with apparent mass 450 kDa (representing 65% of PAI-1 antigen and 85% of PAI activity) was isolated by gel filtration of this mixture. 3) The PAI-1.PAI-1-BP complex was further purified by immunoadsorption on an immobilized murine monoclonal antibody directed against PAI-1 (MA-7D4) and by elution with 4 M KSCN. 4) The complex was then dissociated by addition of excess human tissue-type plasminogen activator (t-PA), and t-PA and PAI-1 antigen (t-PA.PAI-1 complexes and free t-PA and PAI-1) were removed by immunoadsorption on monoclonal antibodies directed against t-PA (MA-62E8) and against PAI-1 (MA-7D4 and MA-12A4). Sodium dodecyl sulfate-gel electrophoresis of the purified material under nonreducing conditions revealed two bands with apparent mass approximately equal to 150 kDa and two bands with mass 74 and 68 kDa. Reduced sodium dodecyl sulfate-gel electrophoresis displayed two main bands with apparent masses of 73 and 64 kDa. The PAI-1-BP reacts with urea-treated, but not with inactive PAI-1. t-PA dissociates the complex between PAI-1 and PAI-1-BP. PAI-1 in complex with PAI-1-BP is 2-3-fold more stable at 37 degrees C than purified PAI-1, suggesting that PAI-1-BP may stabilize PAI-1 in blood. The concentration of PAI-1-BP in plasma determined by titration with PAI-1 is approximately 130 mg/liter. The isolated PAI-1-BP was shown to be identical to S protein (vitronectin) both by cross-reactivity with monospecific rabbit antisera and by NH2-terminal amino acid sequence analysis. The gel filtration behavior, mobility on sodium dodecyl sulfate-gel electrophoresis, and concentration in plasma suggest that PAI-1-BP is a multimer (presumably a dimer) of S protein accounting for approximately 35% of the S protein in plasma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459123

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  88 in total

Review 1.  Molecular basis of thrombolytic therapy.

Authors:  H R Lijnen; D Collen
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

2.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

3.  Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts.

Authors:  Yoshihide Asano; Hironobu Ihn; Kenichi Yamane; Masahide Kubo; Kunihiko Tamaki
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

4.  A vitronectin-receptor-related molecule in human placental brush border membranes.

Authors:  O A Vanderpuye; C A Labarrere; J A McIntyre
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

5.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.

Authors:  Lawrence C Thompson; Sumit Goswami; David S Ginsberg; Duane E Day; Ingrid M Verhamme; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

6.  Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.

Authors:  Sanjeev Sethi; Jeffrey D Gamez; Julie A Vrana; Jason D Theis; H Robert Bergen; Peter F Zipfel; Ahmet Dogan; Richard J H Smith
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

7.  Effects of steroid ablation and progestin replacement on the transcriptome of the primate corpus luteum during simulated early pregnancy.

Authors:  C V Bishop; R A Aazzerah; L M Quennoz; J D Hennebold; R L Stouffer
Journal:  Mol Hum Reprod       Date:  2013-11-12       Impact factor: 4.025

Review 8.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

9.  Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?

Authors:  Daniel I Simon; Norman M Simon
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

10.  Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion.

Authors:  J Schneiderman; G M Bordin; I Engelberg; R Adar; D Seiffert; T Thinnes; E F Bernstein; R B Dilley; D J Loskutoff
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.